Friday, July 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “treatment”

2,520 pharma patents match "treatment" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,520
Index total 30,257
Page 5 / 105

Quick answer

This filtered view shows 2,520 pharmaceutical patents matching "treatment" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,520 results for “treatment” · 30,257 patents in full index Clear search

  1. US 12291548

    Compounds, compositions, and methods for the treatment of disease

    Sperovie Biosciences, Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  2. US 12290651

    Devices and methods for the treatment of body surface disorders

    Verrica Pharmaceuticals Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  3. US 12290538

    Methods and products for treatment of gastrointestinal disorders

    Finch Therapeutics Holdings LLC · Granted May 6, 2025 · Expires May 1, 2045

    granted
  4. US 12290596

    Compositions and methods for the treatment of opioid overdose

    Indivior UK Limited · Granted May 6, 2025 · Expires May 1, 2045

    granted
  5. US 12290551

    Methods for imaging and treatment of somatostatin-receptor positive tumors

    Corcept Therapeutics Incorporated · Granted May 6, 2025 · Expires May 1, 2045

    granted
  6. US 12291507

    Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency

    CENTESSA PHARMACEUTICALS (UK) LIMITED · Granted May 6, 2025 · Expires May 1, 2045

    granted
  7. US 12292445

    Methods of selecting subjects for treatment with metabolomic modulators

    The Regents of the University of California · Granted May 6, 2025 · Expires May 1, 2045

    granted
  8. US 12285490

    ASH1L degraders and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  9. US 12286402

    Compounds and their use for the treatment of alpha1-antitrypsin deficiency

    CENTESSA PHARMACEUTICALS (UK) LIMITED · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  10. US 12285397

    Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

    OVID THERAPEUTICS INC. · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  11. US 12286479

    Treatment with anti-α4β7 antibody

    Takeda Pharmaceutical Company Limited · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  12. US 12286630

    Treatment methods for muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  13. US 12286406

    Inhibitors of receptor interacting protein kinase I for the treatment of disease

    The Board of Regents of the University of Texas System · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  14. US 12286407

    Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases

    The Regents of the University of California · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  15. US 12280063

    Anti-retroviral therapies and reverse transcriptase inhibitors for treatment of Alzheimer's disease

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  16. US 12279630

    Treatment and prevention of seed allergies

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  17. US 12280029

    Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

    INSTITUT PASTEUR DE MONTEVIDEO · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  18. US 12281079

    Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer

    Lead Discovery Center GmbH · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  19. US 12280046

    Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease

    CRINETICS PHARMACEUTICALS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  20. TW 202515903

    Anti-PD-1-based treatment before and after surgery

    BEIGENE SWITZERLAND GMBH [CH] · Granted Apr 16, 2025 · Expires Apr 11, 2045

    granted
  21. US 12274735

    IL-4-fusion formulations for treatment of central nervous system (CNS) tumors

    Medicenna Therapeutics Inc. · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  22. US 12275685

    Oligo-benzamide analogs and their use in cancer treatment

    The Board of Regents of the University of Texas System · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  23. US 12274684

    Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

    United Therapeutics Corporation · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  24. US 12274725

    Zika virus strains for treatment of glioma

    The Board of Regents of the University of Texas System · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted